These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 1330562

  • 1. In vitro activity of the new glycopeptide decaplanin.
    Neu HC, Chin NX, Niu WW.
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of LY264826 compared to other glycopeptides and daptomycin.
    Chin NX, Neu HC.
    Diagn Microbiol Infect Dis; 1991 May; 14(2):181-4. PubMed ID: 1651826
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of LY146032 (daptomycin), a new peptolide.
    Ehlert F, Neu HC.
    Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
    [Abstract] [Full Text] [Related]

  • 4. Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.
    Niu WW, Neu HC.
    Antimicrob Agents Chemother; 1991 May; 35(5):998-1000. PubMed ID: 1649577
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.
    Sanchez ML, Wenzel RP, Jones RN.
    Antimicrob Agents Chemother; 1992 Apr; 36(4):873-5. PubMed ID: 1386973
    [Abstract] [Full Text] [Related]

  • 6. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A, Colao MG, Orsi A, Dei R, Giganti E, Parenti F.
    J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
    [Abstract] [Full Text] [Related]

  • 7. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K, Braveny I.
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [Abstract] [Full Text] [Related]

  • 8. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D, Brown DF, Soussy CJ.
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
    Jorgensen JH, Maher LA, Redding JS.
    Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
    Shonekan D, Mildvan D, Handwerger S.
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 13. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
    Kenny MT, Dulworth JK, Brackman MA.
    Diagn Microbiol Infect Dis; 1991 Dec; 14(1):29-31. PubMed ID: 1826479
    [Abstract] [Full Text] [Related]

  • 15. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.
    Low DE, McGeer A, Poon R.
    Antimicrob Agents Chemother; 1989 Apr; 33(4):585-8. PubMed ID: 2543286
    [Abstract] [Full Text] [Related]

  • 16. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
    Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Zweifel MJ, Wilkie SC, Rodriguez MJ, Thompson RC, Cooper RD.
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
    [Abstract] [Full Text] [Related]

  • 17. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC, Ribou G, Masquelier B.
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [Abstract] [Full Text] [Related]

  • 18. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC.
    Drugs; 1997 May; 54 Suppl 6():11-20. PubMed ID: 9474477
    [Abstract] [Full Text] [Related]

  • 19. In vitro evaluation of teicoplanin and other antimicrobials against streptococci group D bacteria.
    Breyer S, Georgopoulos A, Graninger W.
    Drugs Exp Clin Res; 1987 May; 13(8):479-81. PubMed ID: 2962843
    [Abstract] [Full Text] [Related]

  • 20. Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.
    Mini E, Novelli A, Mazzei T, Periti P.
    Eur J Clin Microbiol Infect Dis; 1989 Mar; 8(3):256-60. PubMed ID: 2523807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.